Get the Stockscreener App
1.46
4.58%
-0.07
After Hours:
1.44
-0.02
-1.37%
Metavia Inc stock is traded at $1.46, with a volume of 53,226.
It is down -4.58% in the last 24 hours and up +0.00% over the past month.
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
See More
Previous Close:
$1.53
Open:
$1.565
24h Volume:
53,226
Relative Volume:
1.34
Market Cap:
$12.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.30%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.4237
$1.60
1-Week Range:
$1.4237
$1.65
52-Week Range:
$1.29
$2.75
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.46 | 12.58M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks
MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus
MetaVia Inc. (MTVA) reports earnings - Quartz
Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV
Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire
Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV
New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV
Ears Ringing? Diet Changes Might Reduce Risk Of Tinnitus - 69News WFMZ-TV
Combination Therapy Recommended For Migraines - 69News WFMZ-TV
Dance Soothes Agitation In Alzheimer's Patients - 69News WFMZ-TV
MetaVia (MTVA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Stock market today: Wall Street rises ahead of Fed announcement - 69News WFMZ-TV
Wall Street tumbles 10% below its record for first 'correction' since 2023 on Trump's trade war - 69News WFMZ-TV
Stocks' sell-off worsens as Wall Street wonders how much pain Trump will accept for economy - WFMZ.com
Stock market today: Wall Street ends its wild week with what else but more swings - WFMZ.com
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
MTVA stock touches 52-week low at $1.48 amid sharp yearly decline - Investing.com Canada
MTVA stock touches 52-week low at $1.48 amid sharp yearly decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NeuroBo Pharmaceuticals : Statement of Changes in Beneficial OwnershipForm 4 -July 28, 2022 at 09:34 pm EDT - Marketscreener.com
2024 Initations - Zacks Small Cap Research
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025 - MSN
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
MetaVia Advances Therapeutics with Promising Trial Updates - TipRanks
Walgreens tops Wall Street's expectations as drugstore chain continues turnaround plan - 69News WFMZ-TV
Greece bans windowless basements, freezes central Athens licenses in overhaul of short-term rentals - 69News WFMZ-TV
US added a strong 256,000 jobs in December as unemployment rate dipped to 4.1% - 69News WFMZ-TV
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - The Herald Journal
Childhood Smoking Ups COPD Risk - 69News WFMZ-TV
Advisory firm recommends changes at Air Products - 69News WFMZ-TV
Can Doctors Estimate Life Expectancy After a Dementia Diagnosis? - 69News WFMZ-TV
Stock market today: World shares slide further as rate cut, tariff worries hit market sentiment - 69News WFMZ-TV
Tanker hit by Houthi rebels that threatened a Red Sea oil spill has been salvaged - 69News WFMZ-TV
How the wildfires in the Los Angeles area could affect California's home insurance market - 69News WFMZ-TV
Meloni says Italy is exploring deals on telecoms security, but denies private talks with Musk - 69News WFMZ-TV
Revenue Surge & Breakthrough Margins Fuel Growth in Critical Care Tech - Streetwise Reports
Nearly half of Americans carry spare underwear for emergencies - 69News WFMZ-TV
‘Mufasa’ and ‘Sonic 3’ rule first weekend of 2025 - 69News WFMZ-TV
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
What is HC Wainwright’s Estimate for MetaVia Q4 Earnings? - Defense World
Analysts Offer Predictions for MetaVia FY2024 Earnings - Defense World
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
Metavia Inc Stock (MTVA) Financials Data
There is no financial data for Metavia Inc (MTVA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):